{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:33:20Z","timestamp":1789205600823,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2024.1398879","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:06:13Z","timestamp":1715231173000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup"],"prefix":"10.3389","volume":"15","author":[{"given":"Jianghua","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease-adapted study","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"LANCET Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"887","DOI":"10.2217\/fon-2023-0082","article-title":"Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma","volume":"19","author":"Facon","year":"2023","journal-title":"FUTURE Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s12325-022-02083-8","article-title":"Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: a systematic literature review and network meta-analysis","volume":"39","author":"Facon","year":"2022","journal-title":"Adv. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.clml.2023.02.009","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible asian patients with newly diagnosed multiple myeloma: the phase 3 OCTANS study","volume":"23","author":"Fu","year":"2023","journal-title":"Cl. Lymph. MYELOM Leuk."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"97","author":"Goel","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"LANCET Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1003454","DOI":"10.1371\/journal.pmed.1003454","article-title":"Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): interim analysis of an open-label randomised controlled trial","volume":"18","author":"Jackson","year":"2021","journal-title":"PLOS Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"LANCET"},{"key":"B11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2020.8008","article-title":"Caution with routine use of daratumumab for newly diagnosed high-risk multiple myeloma","volume":"7","author":"Mohyuddin","year":"2021","journal-title":"JAMA Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"LANCET Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"BLOOD"},{"key":"B15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA-CANCER J. Clin."},{"key":"B16","doi-asserted-by":"publisher","first-page":"8054","DOI":"10.1200\/jco.2022.40.16_suppl.8054","article-title":"Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with\/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211)","volume":"40","author":"Usmani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"LANCET Haematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1007\/s12325-022-02195-1","article-title":"Triplet RVd induction for transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"39","author":"Yang","year":"2022","journal-title":"Adv. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1182\/blood.2020008733","article-title":"How I treat high-risk multiple myeloma","volume":"139","author":"Zamagni","year":"2022","journal-title":"BLOOD"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s12325-021-01699-6","article-title":"Cost-effectiveness analysis of adding daratumumab to a regimen of bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma","volume":"38","author":"Zeng","year":"2021","journal-title":"Adv. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1398879\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:06:15Z","timestamp":1715231175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1398879\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":20,"alternative-id":["10.3389\/fphar.2024.1398879"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1398879","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"article-number":"1398879"}}